Tower Research Capital LLC TRC Trims Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Tower Research Capital LLC TRC decreased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 74.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,331 shares of the company’s stock after selling 6,821 shares during the period. Tower Research Capital LLC TRC’s holdings in Viridian Therapeutics were worth $51,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Swiss National Bank increased its stake in shares of Viridian Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 67,200 shares of the company’s stock worth $1,464,000 after purchasing an additional 800 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its stake in shares of Viridian Therapeutics by 2.9% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 29,553 shares of the company’s stock worth $453,000 after purchasing an additional 823 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Viridian Therapeutics by 9.7% in the fourth quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock worth $378,000 after purchasing an additional 1,545 shares in the last quarter. Silverarc Capital Management LLC grew its stake in Viridian Therapeutics by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 47,438 shares of the company’s stock valued at $728,000 after acquiring an additional 2,438 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Viridian Therapeutics by 17.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,227 shares of the company’s stock valued at $448,000 after acquiring an additional 4,412 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. B. Riley reduced their price objective on shares of Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Wedbush boosted their price objective on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, March 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, February 29th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $36.60.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock traded down $0.34 during mid-day trading on Tuesday, hitting $13.26. 898,244 shares of the company traded hands, compared to its average volume of 926,235. Viridian Therapeutics, Inc. has a one year low of $10.93 and a one year high of $28.99. The stock has a market cap of $832.33 million, a price-to-earnings ratio of -2.49 and a beta of 1.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.26 and a current ratio of 18.26. The stock has a fifty day moving average price of $16.96 and a 200-day moving average price of $17.55.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.37). Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.15 million. During the same quarter in the previous year, the firm earned ($1.13) earnings per share. The company’s revenue for the quarter was down 31.4% compared to the same quarter last year. On average, equities analysts predict that Viridian Therapeutics, Inc. will post -4.39 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.